A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

<p>Abstract</p> <p>Background</p> <p>5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy...

Full description

Bibliographic Details
Main Authors: Hosein Peter J, Macintyre Jessica, Kawamura Carolina, Maldonado Jennifer, Ernani Vinicius, Loaiza-Bonilla Arturo, Narayanan Govindarajan, Ribeiro Afonso, Portelance Lorraine, Merchan Jaime R, Levi Joe U, Rocha-Lima Caio M
Format: Article
Language:English
Published: BMC 2012-05-01
Series:BMC Cancer
Subjects:
Pancreatic ductal carcinoma
neoadjuvant therapy
surgery
radiation therapy
Online Access:http://www.biomedcentral.com/1471-2407/12/199

Internet

http://www.biomedcentral.com/1471-2407/12/199

Similar Items